Library / regulatory-reference
Italy: Italian Medicines Agency (AIFA)
Audience: administrators-policy, researchers-scientists ยท Review state: published
The national authority
AIFA, the Italian Medicines Agency, is Italy's national authority for medicines, operating under the supervision of the Ministry of Health.
Italy's market sits inside the European single market, and the agency combines regulation with pricing and reimbursement negotiation for medicines paid for by the national health service.
How products enter the market
Medicines require marketing authorization through national or European procedures after evaluation of quality, safety and efficacy, and the agency also oversees clinical-trial authorization and access to innovative medicines.
Post-market work includes pharmacovigilance, monitoring of medicine shortages and public notices on safety and quality concerns.
Regional and international role
The agency contributes to the European regulatory network and to shared assessments.
Its joint role in authorization and price negotiation makes it a useful reference for linking market access to reimbursement.
Using this profile
The authority publishes regulations, registers and alerts in Italian and English through its official portal, which is the primary source for current rules and listed in this profile's internal reference record.
For cross-country comparison: Italy illustrates the regulator-negotiator: one agency spanning authorization, pricing and reimbursement.
Limitations
Educational profile of a national regulatory system, current as of drafting. It simplifies routes and classes and is not legal, regulatory, or clinical advice. Filing and compliance decisions must be confirmed against the authority's current published rules and, where needed, professional regulatory counsel.